Email: cspc@cspc.cn
News
News Center
Jul. 13
2022
CSPC's COVID-19 Vaccine Approved for Clinical Trials
On April 3, 2022, CSPC Pharmaceutical Group Co., Ltd. (Stock code 1093. HK) announced that the COVID-19 mRNA vaccine SYS6006 ("the product") developed by the Group was approved by the National Medical Products Administration for clinical trials in China.
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
